Turn Therapeutics Inc. TTRX

Turn Therapeutics Inc. (TTRX) appoints former CDC Director Robert R. Redfield, M.D. as Chief Scientific Officer. Former CDC director appointment as CSO adds high-level scientific expertise and boosts company credibility in therapeutics.

Turn Therapeutics (TTRX) announces peer-reviewed research showing GX-03 selectively reduces key drivers of skin inflammation and itch. Positive peer-reviewed GX-03 data supports dermatology pipeline progress and may lift near-term sentiment.

Turn Therapeutics Inc. provides corporate updates and reports second quarter 2026 financial results. Quarterly financial results may moderately shift investor views on operations and valuation.

Turn Therapeutics refines GX-03 eczema trial after interim data and targets 2026 readout. Trial refinement and 2026 readout signal moderate progress on core eczema candidate without immediate market shift.

Turn Therapeutics Inc. (TTRX) stock rose after reporting positive AD data and expanding clinical trials. Positive AD data release and trial expansion signal major progress likely to drive significant gains in valuation and pipeline momentum.

Turn Therapeutics completes interim Phase 2 review and expands GX-03 study in atopic dermatitis. Interim Phase 2 completion and GX-03 expansion in atopic dermatitis mark clinical progress capable of shifting company trajectory and investor outlook.

Turn Therapeutics finalizes Stage 2 design and expands GX-03 Phase 2 program in atopic dermatitis. GX-03 Phase 2 expansion advances Turn Therapeutics' lead dermatology candidate toward potential approval and commercialization.

Turn Therapeutics schedules webcast to present interim analysis and optimized Stage 2 design for GX-03 atopic dermatitis treatment. GX-03 trial update webcast may shift near-term sentiment on pipeline progress without altering core trajectory.

Turn Therapeutics reported interim analysis findings and an adaptive optimization strategy from its Phase 2 GX-03 trial in moderate-to-severe atopic dermatitis. Phase 2 trial progress and adaptive strategy directly influence Turn Therapeutics' regulatory path and market prospects for its core dermatitis treatment.

Turn Therapeutics publishes peer-reviewed data in Journal of Dermatological Treatment demonstrating GX-03 activity in IL-36 associated inflammatory model. Peer-reviewed publication validates GX-03 technology and may lift sentiment yet lacks clinical or revenue milestones.

Turn Therapeutics appoints physician-scientist and former FDA Commissioner Dr. Stephen M. Hahn as Executive Clinical and Regulatory Lead. Former FDA Commissioner Dr. Stephen M. Hahn joins Turn Therapeutics to lead clinical and regulatory efforts.

Turn Therapeutics Inc. (TTRX) reported first quarter 2026 financial results, including key metrics on revenue, expenses, cash position, and provided updates on clinical pipeline progress, partnerships, and strategic initiatives. Quarterly financial results and corporate updates moderately influence financial performance and investor sentiment without fundamentally altering long-term trajectory.

Turn Therapeutics Inc. (TTRX) reported full year 2025 financial results and provided corporate updates. Full-year financial results and corporate updates moderately influence financial performance and market sentiment without transformative changes.

Turn Therapeutics Inc. (TTRX) secures up to $25 million in financing from Avenue Capital Group. Securing up to $25 million in financing provides critical capital to support Turn Therapeutics' operations, R&D, and growth trajectory.

Turn Therapeutics discloses GX-03 Phase II eczema trial data timeline and details non-systemic topical drug strategy. GX-03 Phase II eczema data timeline and topical strategy update provide moderate pipeline visibility for TTRX.

Turn Therapeutics Inc. (TTRX) appointed Dr. Robert Redfield, former CDC Director, as Senior Advisor of Health Policy and Regulatory Affairs to strengthen its expertise in navigating regulatory landscapes and health policy. Appointing former CDC Director Robert Redfield bolsters regulatory strategy and credibility, potentially accelerating approvals and enhancing investor confidence.

Multiple insiders at Turn Therapeutics Inc. (TTRX) have recently purchased shares of the company's stock, signaling potential confidence in its future performance. This activity may indicate positive sentiment regarding the company's prospects and could influence market perception. Insider buying typically reflects confidence in the company's future, which may moderately influence market sentiment and performance.

Turn Therapeutics Inc. (TTRX) announced corporate and pipeline updates along with its outlook for 2026 ahead of the 44th Annual J.P. Morgan Healthcare Conference. The company highlighted advancements in its product pipeline and strategic initiatives aimed at enhancing its market position and financial performance. Significant strategic moves and product developments are expected to impact the company's future performance and investor sentiment.

Turn Therapeutics Inc. (TTRX) insiders hold a significant 59% stake in the company and have been actively purchasing additional shares. This trend indicates strong confidence among insiders regarding the company's future prospects and may positively influence market sentiment. Insider buying at this level suggests significant confidence in the company's future, which could impact investor sentiment and market performance.

Turn Therapeutics Inc. has appointed Martin Dewhurst to its Board of Directors, enhancing its leadership team. Dewhurst brings extensive experience in the biotechnology sector, having held senior roles at various companies. His expertise is expected to contribute to Turn Therapeutics' strategic direction and growth initiatives. The appointment of a seasoned executive like Martin Dewhurst may positively influence the company's strategic direction and operational effectiveness.

Turn Therapeutics Inc. (TTRX) reported its financial results for the third quarter of 2025, highlighting key metrics and corporate updates. The company showcased progress in its product pipeline and strategic initiatives aimed at enhancing market presence. Financial performance indicators reflected ongoing efforts to optimize operations and drive growth. Management provided insights into future plans and expectations, emphasizing commitment to innovation and shareholder value. Financial results and corporate updates indicate moderate influence on future performance and market positioning.

Turn Therapeutics Inc.'s GX-03 technology has been recognized by Patient Care Online Magazine as one of the five novel mechanisms reshaping the treatment of atopic dermatitis. This acknowledgment highlights the potential of GX-03 in addressing this prevalent skin condition, positioning Turn Therapeutics as a key player in the evolving landscape of dermatological therapies. Recognition of GX-03 as a novel mechanism in atopic dermatitis treatment could significantly enhance Turn Therapeutics' market position and investor sentiment.

Turn Therapeutics CEO Bradley Burnam engaged in a discussion with Dr. Robert Redfield, former Director of the CDC, focusing on public health challenges and the role of innovative therapies in addressing them. The conversation highlighted the importance of collaboration between biotech companies and health authorities to tackle pressing health issues. Insights from Dr. Redfield emphasized the need for effective communication and strategic partnerships in the healthcare sector. The discussion may influence Turn Therapeutics' strategic positioning and partnerships in the healthcare landscape.

Turn Therapeutics Inc. has appointed Andrew Scott as Vice President of Corporate Communications. Scott brings extensive experience in capital markets and corporate communications, having previously held senior roles at various companies. His appointment is expected to enhance Turn Therapeutics' strategic communications and investor relations efforts as the company continues to advance its initiatives in the biotechnology sector. The appointment of a seasoned executive in corporate communications may moderately influence the company's market positioning and investor relations.

Turn Therapeutics Inc. has entered into a global supply, development, and license agreement with Medline, a leading medical-surgical product manufacturer and distributor. This partnership aims to enhance the distribution and development of Turn Therapeutics' products, potentially expanding their market reach and operational capabilities. The agreement with Medline represents a significant strategic move that could enhance Turn Therapeutics' market position and operational growth.

Turn Therapeutics Inc. (TTRX) provided a shareholder update detailing progress in clinical trials and strategic initiatives. The company highlighted advancements in its product pipeline and ongoing collaborations aimed at enhancing its market position. Key milestones were achieved, reinforcing TTRX's commitment to innovation and growth in the therapeutic landscape. Significant advancements in clinical trials and strategic initiatives are likely to enhance the company's market position and investor sentiment.

Turn Therapeutics has appointed Dr. Kent Kester to its Board of Directors. Dr. Kester brings extensive experience in clinical development and regulatory affairs, having previously held leadership roles in various biotechnology companies. His expertise is expected to enhance Turn Therapeutics' strategic direction and support its growth initiatives. The appointment of Dr. Kester is likely to influence the company's strategic direction and operational capabilities.

Turn Therapeutics has appointed Arthur Golden to its Board of Directors, enhancing its leadership team. Golden brings extensive experience in the biotechnology sector, which is expected to support the company's strategic initiatives and growth. The appointment of a seasoned professional like Arthur Golden may positively influence Turn Therapeutics' strategic direction and operational effectiveness.

Turn Therapeutics (TTRX) is set to begin trading on the Nasdaq today, marking a significant milestone for the company as it enters the public market. This development is expected to enhance its visibility and access to capital, potentially accelerating its growth and innovation in the therapeutic sector. Commencing trading on Nasdaq is a major strategic move that could significantly alter the company's trajectory and investor sentiment.